In Vivo Anti Cancer Potential of Pyrogallol in Murine Model of Colon Cancer

Asian Pac J Cancer Prev. 2019 Sep 1;20(9):2645-2651. doi: 10.31557/APJCP.2019.20.9.2645.

Abstract

Background: Colon cancer is aggressive and it causes 0.5 million deaths per year. Practicing natural medicines for cancer treatment is safer than conventional drugs. World health organization emphasizes on the importance of practicing natural medicines and developing natural product based drugs for cancer treatment. Recently we reported an anti colon cancer activity associated with pyrogallol isolated from medicinal plant Acacia nilotica in HT-29 cells in vitro. To extend our observation in this study we evaluated in vivo colon tumor remission property of acetone extract of A. nilotica (ACE) and pyrogallol. Materials and Methods: In vivo toxicity of ACE and pyrogallol was assessed and In vivo tumor remission activity of ACE and pyrogallol was determined in murine model. Results: Mice were tolerated different doses of ACE and pyrogallol. Tumor size was considerably reduced in pyrogallol treated mice similar to doxorubicin. Tumor bearing mice treated with ACE and pyrogallol showed mild decline in body weight. Conclusion: Pyrogallol was found to be an effective anti colon cancer agent with less toxicity.

Keywords: Acacia nilotica; Colon cancer; Helicobacter pylori; Pyrogallol; Toxicity.

MeSH terms

  • Acacia / chemistry*
  • Animals
  • Antioxidants / pharmacology*
  • Apoptosis
  • Cell Proliferation
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / pathology
  • Disease Models, Animal
  • Female
  • Humans
  • Mice
  • Plant Extracts / pharmacology*
  • Plant Leaves / chemistry
  • Pyrogallol / pharmacology*
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Substances

  • Antioxidants
  • Plant Extracts
  • Pyrogallol